Title of study


Epidemiology and Genetics of Alzheimer? Disease

Acronym for cohort


Name of Principal Investigator - Title


Prof

Name of Principal Investigator - First name


Vladimir

Name of Principal Investigator - Last name


Janout

Address of institution -Institution


Faculty of medicine

Address of institution - Street address


Syllybova 19

Address of institution - City


Syllybova 19

Address of institution - Postcode


70300

Country


Czech Republic

Website


www.osu.cz

Contact email


[email protected]

Funding source


Ministry of Health

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?


Alzheimer's disease and other dementias

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)


The role of risk factors in development of Alzheimer? disease

Q2b. What distinguishes this case-control study from other studies?


Both epidemiological and genetic data

Q3a. i) Number of publications that involve use of your cohort to date


15

Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)


Epidemiology and Genetics of Alzheimer? disease|Genetics and epidemiology of Alzheimer? disease Prof.V.Janout, Faculty of Medicine University of Ostrava|Genetics and epidemiology of mild cognitive impairment Prof.V.Janout, Faculty of Medicine Univerity of Ostrava

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available


web of science

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study


Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:


60

Q4a. Study criteria: what is the age range of participants at recruitment? To:


85

Q4b. Study criteria: what are the inclusion criteria?


no other form of dementia, minimental test less than 24

Q4c. Study criteria: what are the exclusion criteria?


other form of dementia , minimental test more than 24

Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?


1,001-5,000

Q5b. What is the expected number of control participants?


501-1,000

Q6a. Please describe what measures are used to characterise participants


clinical diagnosis of Alzheimer? disease

Q6b. Are there additional measures for participants with the clinical disorder?


Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?


No

If YES please specify


Q7. What is the study design?


Prospective cohort|Genome wide association study (GWAS)|Age|Sex

Q8. Are your cases matched by


Cogntive function

Q9a. Does your study includes a specialised subset of control participants?


No

Q9b. If your study includes a specialised subset of control participants please describe


Q10a. Is data collection for this study


Data analysis ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?


Yes - funding applied for

Q11. Are data collected


Only through the study|Through links to medical records

Q12. Is there a system in place to enable re-contact with patients for future studies?


No

Q13a. Please give information on data stored in a database (1)


Data summarised in database

% Available


Q13a. Please give information on data stored in a database (2)


No

% Available


Q13a. Please give information on data stored in a database (3)


Database on spreadsheet (e.g. excel)

% Available


Q13a. Please give information on data stored in a database (4)


No

% Available


Q13a. Please give information on data stored in a database (5)


No

% Available


Please specify language used


% Available


Q13b. Please give information on how data is held as individual records


No

% Available


Q14a. Are data available to other groups?


No

Q14b. If data is available to other groups what is the access policy/mechanisms for access?


Q15. What data sharing policy is specified as a condition of use?


No policy exists

Q16a. Are tissues/samples/DNA available to other groups?


Yes

Q16b i) If yes, please describe below


Living donors: DNA

Q16b. ii) In what form are tissues/samples/DNA supplied?


Primary Samples: Stabilised samples (frozen or fixed)

Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?


No

Q17. Is information on biological characteristics available to other groups?


No

Export as PDF